DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
The precise insertion of DNA sequences using the homology-directed repair (HDR) pathway is one potential use of the CRISPR/Cas genome editing technology. Various circumstances could influence the ...
- Stimulating gene editing by homology-directed repair (HDR) has the potential advantage of being able to achieve any type of edit, including gene insertion - ARCUS approach potentially offers broader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback